Cargando…

Estimating the optimal perioperative chemotherapy utilization rate for muscle‐invasive bladder cancer

BACKGROUND: Identifying optimal chemotherapy (CT) utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle‐invasive bladder cancer (MIBC). METHODS: The Ontario Cancer Registry and linked treated records...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karim, Safiya, Mackillop, William J., Brennan, Kelly, Peng, Yingwei, Siemens, D. Robert, Krzyzanowska, Monika K., Booth, Christopher M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797575/ https://www.ncbi.nlm.nih.gov/pubmed/31472011 http://dx.doi.org/10.1002/cam4.2449

Ejemplares similares

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study
por: Brennan, Kelly, et al.
Publicado: (2018)

Peri-Operative Chemotherapy for Bladder Cancer: A Survey of Providers to Determine Barriers and Enablers
por: Walker, Melanie, et al.
Publicado: (2018)

Perioperative immunotherapy for muscle-invasive bladder cancer
por: Kim, In-Ho, et al.
Publicado: (2020)

Emerging perioperative therapeutic approaches in muscle invasive bladder cancer
por: Patil, Goutham, et al.
Publicado: (2022)

Population‐based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non‐metastatic muscle‐invasive bladder cancer
por: Benidir, Tarik, et al.
Publicado: (2021)

The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
por: D'Andrea, David, et al.
Publicado: (2022)

Sexual Dimorphism in Outcomes of Non–muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint
por: Chenard, Stephen, et al.
Publicado: (2021)

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer
por: Dudek, Aleksandra M., et al.
Publicado: (2018)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
por: von Deimling, Markus, et al.
Publicado: (2023)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

The optimal management of variant histology in muscle invasive bladder cancer
por: Tiwari, Raj Vikesh, et al.
Publicado: (2020)

Perioperative therapy in muscle invasive bladder cancer
por: Chatterjee, Ambarish, et al.
Publicado: (2021)

Perioperative immunotherapy in muscle-invasive bladder cancer
por: Lee, Hyung Ho, et al.
Publicado: (2020)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
por: Zhao, Lulu, et al.
Publicado: (2023)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
por: Fiteni, Frédéric, et al.
Publicado: (2016)

Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
por: Lu, Jun, et al.
Publicado: (2020)

Prognostic significance of bladder neck involvement in non‐muscle‐invasive bladder cancer: A SEER database analysis with 19,919 patients
por: Zhan, Xiangpeng, et al.
Publicado: (2021)

Outcome of patients with nonmetastatic muscle‐invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin‐based chemotherapy and/or radiotherapy: a retrospective analysis
por: Bamias, Aristotle, et al.
Publicado: (2016)

Human Gut Mycobiome and Fungal Community Interaction: The Unknown Musketeer in the Chemotherapy Response Status in Bladder Cancer
por: Bukavina, Laura, et al.
Publicado: (2022)

Inhibition of hypoxia-inducible factor 1α accumulation by glyceryl trinitrate and cyclic guanosine monophosphate
por: Kim, Judy, et al.
Publicado: (2020)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Opium use and risk of bladder cancer: a multi-centre case-referent study in Iran
por: Hadji, Maryam, et al.
Publicado: (2022)

Chemotherapy and terminal skeletal muscle differentiation in WT1‐mutant Wilms tumors
por: Royer‐Pokora, Brigitte, et al.
Publicado: (2018)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
por: Rezaee, Michael E., et al.
Publicado: (2021)

Identification of prognostic biomarkers associated with stromal cell infiltration in muscle‐invasive bladder cancer by bioinformatics analyses
por: Li, Pan, et al.
Publicado: (2020)

Adherence to the WCRF/AICR Cancer Prevention Recommendations and Risk of Recurrence in Non-muscle Invasive Bladder Cancer
por: van Zutphen, Moniek, et al.
Publicado: (2022)

Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
por: Christensen, Emil, et al.
Publicado: (2023)

Prediction of Metastatic Patterns in Bladder Cancer: Spatiotemporal Progression and Development of a Novel, Web-based Platform for Clinical Utility
por: Mason, Jeremy, et al.
Publicado: (2021)

Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China
por: Zhu, Dawei, et al.
Publicado: (2021)

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative
por: Reesink, Daan J., et al.
Publicado: (2021)

Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling
por: Bodzioch, Mariusz, et al.
Publicado: (2021)

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
por: Raphael, Jacques, et al.
Publicado: (2022)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0bb3kaadnculliennaer6salkj